echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Ascletis Announces Submission of U.S. Clinical Trial Application for Fully Self-developed Oral PD-L1 Small Molecule Inhibitor ASC61 for the Treatment of Advanced Solid Tumors

    Ascletis Announces Submission of U.S. Clinical Trial Application for Fully Self-developed Oral PD-L1 Small Molecule Inhibitor ASC61 for the Treatment of Advanced Solid Tumors

    • Last Update: 2022-01-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>/* Style Definitions */ span.


    ASC61 is a potent and highly selective oral PD-L1 small molecule inhibitor that blocks the PD-1/PD-L1 interaction by inducing the formation and endocytosis of PD-L1 dimers
    .


    ASC61 single drug showed significant anti-tumor efficacy in humanized mouse model and other animal models


    Compared with PD-1/PD-L1 antibody injections, oral PD-L1 inhibitor ASC61 has the following advantages: (1) convenient administration, no need to go to the hospital for injection drugs; (2) combined with other oral antitumor drugs Form an all-oral treatment regimen; and (3) be able to adjust the dosage in a timely manner to better manage immune-related adverse events
    .

     "We are very pleased to submit the US clinical trial application for ASC61," said Dr.
    Jinzi Wu, founder, chairman and chief executive officer of Ascletis, "We are advancing the combination of the fatty acid synthase (FASN) inhibitor ASC40 and bevacizumab in the treatment of relapsed The Phase III clinical trial in glioblastoma (rGBM), ASC61 as an oral PD-L1 small molecule inhibitor, will further strengthen Ascletis' oncology pipeline
    .


    "

    About Song Li

    Ascletis is an innovative R&D-driven biotechnology company listed on the Hong Kong Stock Exchange (1672.
    HK), covering the complete value chain from new drug discovery and development to production and commercialization
    .


    Ascletis is committed to the R&D and commercialization of innovative drugs in the fields of viral diseases, nonalcoholic steatohepatitis/primary biliary cholangitis, tumors (oral tumor metabolic checkpoint and immune checkpoint inhibitors), etc.


    1.
    Viral diseases: (1) Hepatitis B (functional cure): Explore a treatment plan with subcutaneous injection of PD-L1 antibody ASC22 and Pegasys® as cornerstone drugs, combined with other target drugs, which is expected to be functional cure for hepatitis B bring about a major breakthrough
    .


    (2) New coronary pneumonia drug pipeline: currently includes (i) marketed ritonavir oral tablet (100 mg); (ii) oral polymerase (RdRp) inhibitor ASC10; (iii) oral protease (3CLpro) inhibitor agent ASC11


    2.
    Non-alcoholic steatohepatitis/primary biliary cholangitis: Ganlai, a wholly-owned subsidiary of Ascletis, focuses on the development and commercialization of innovative drugs in the field of non-alcoholic steatohepatitis
    .


    Gan Lai has three clinical-stage nonalcoholic steatohepatitis drug candidates targeting fatty acid synthase (FASN), thyroid hormone ß receptor (THRß) and farnesoid X receptor (FXR) and three fixed-dose combinations preparation


    3.
    Oncology (oral tumor metabolic checkpoint and immune checkpoint inhibitors): Ascletis has an innovative and differentiated pipeline in the field of tumor therapy, focusing on oral inhibitors of fatty acid synthase that play a key role in tumor lipid metabolism pipeline and a new generation of immune checkpoint inhibitors - oral PD-L1 small molecule inhibitor pipeline
    .

    4.
    Expanded indications: Acne: ASC40 has been approved for Phase II clinical trials for new acne indications following the indications for nonalcoholic steatohepatitis and solid tumors
    .


    For more information, please visit the website: .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.